Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

BUSINESS COMBINATIONS (Narrative) (Details)

v3.24.1
BUSINESS COMBINATIONS (Narrative) (Details)
₪ in Thousands, $ in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 01, 2021
CAD ($)
Dec. 01, 2021
ILS (₪)
Jun. 30, 2022
USD ($)
Mar. 31, 2023
CAD ($)
Mar. 31, 2023
ILS (₪)
Dec. 31, 2023
CAD ($)
Dec. 31, 2022
CAD ($)
Dec. 31, 2021
CAD ($)
[1]
Mar. 31, 2023
ILS (₪)
Jun. 30, 2022
ILS (₪)
Jun. 30, 2022
USD ($)
Dec. 01, 2021
ILS (₪)
Disclosure of detailed information about business combination [line items]                        
Revenues           $ 48,804 $ 54,335 $ 34,053        
Net loss           $ (10,228) (191,301) $ (18,518)        
Oranim Pharm [Member]                        
Disclosure of detailed information about business combination [line items]                        
Percentage of acquisition 51.00% 51.00%                    
Total purchase price $ 4,900                     ₪ 11,900
Accrued purchased consideration     $ 2,003                  
Cash consideration of business combination $ 2,100 ₪ 5,200   $ 2,100 ₪ 5,200              
Value of common shares issued in business combination       $ 700         ₪ 1,500 ₪ 5,200 $ 2,100  
Revenues             1,410          
Net loss             $ 46          
Percentage of discount on Put option exercise price in first 12 months           15.00%            
Percentage of extra agreed value on Call option exercise price in first 12 months           15.00%            
Percentage of discount on Put option exercise price in next 12 months           10.00%            
Percentage of extra agreed value on Call option exercise price in next 12 months           10.00%            
Percentage of discount on Put option exercise price in last 12 months           2.50%            
Percentage of extra agreed value on Call option exercise price in last 12 months           2.50%            
[1] Reclassified in respect of discontinued operations - see Note 25.